API 0.74% $1.35 australian pharmaceutical industries limited

Stellar run, page-13

  1. 2,000 Posts.
    lightbulb Created with Sketch. 27
    we always hope of a continuous rise like this in our investments, but when it happens this steeply, we start to worry about it happening too fast and unsustainably.

    If you read the last profit guidance (AGM preso) API expect NPAT to increase 20 - 25% for 1H15. The increase in SP we are witnessing is, I believe, a rerating of this premier stock, possibly back to what it was pre-GFC when it maxed at around $3.00 - $3.50 with a support level of around $2 long term. Of course, at that time the divvies were around 6c, compared to the current 2c, (both half year) but with the strong divvy growth that API are achieving, I look forward to the divvy getting up to those levels again, underpinning a rise in the SP to higher levels still.
 
watchlist Created with Sketch. Add API (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.